Baseline demographic and clinical features
| BMT (n=116) | GPi DBS (n=80) | STN DBS (n=84) | |||||
|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | p Value | |
| Age (years) | 62.3 | 8.9 | 61.3 | 8.9 | 61.3 | 8.5 | 0.68 |
| Education (years) | 14.8 | 3.0 | 14.3 | 3.1 | 15.2 | 3.3 | 0.17 |
| Years since diagnosis | 12.8 | 5.5 | 11.0 | 4.7 | 11.0 | 5.0 | 0.02 |
| Years on PD medication | 12.2 | 5.3 | 10.4 | 4.6 | 10.1 | 4.4 | 0.004 |
| Hoehn-Yahr off medication | 3.3 | 0.9 | 3.2 | 0.8 | 3.4 | 0.9 | 0.48 |
| Hoehn-Yahr on medication | 2.4 | 0.5 | 2.3 | 0.7 | 2.3 | 0.6 | 0.73 |
| Blinded on med UPDRS III | 23.2 | 10.5 | 22.2 | 12.4 | 21.2 | 11.8 | 0.49 |
| Blinded off med UPDRS III | 43.1 | 11.2 | 41.6 | 12.6 | 42.8 | 16.7 | 0.72 |
| Total levodopa dosage (mg) | 1290.1 | 550.2 | 1284.0 | 490.7 | 1291.5 | 549.8 | >0.99 |
BMT, best medical therapy; DBS, deep brain stimulation; GPi, globus pallidus interna; PD, Parkinson's disease; STN, subthalamic nucleus; UPDRS, unified Parkinson's disease rating scale.